Gitterman Wealth Management LLC Trims Position in Johnson & Johnson (NYSE:JNJ)

Gitterman Wealth Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 5.0% during the 4th quarter, HoldingsChannel reports. The firm owned 15,809 shares of the company’s stock after selling 835 shares during the quarter. Johnson & Johnson accounts for about 1.1% of Gitterman Wealth Management LLC’s investment portfolio, making the stock its 6th largest holding. Gitterman Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,478,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in JNJ. Massachusetts Wealth Management increased its stake in Johnson & Johnson by 4.2% during the third quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock worth $2,508,000 after acquiring an additional 650 shares during the last quarter. Warren Street Wealth Advisors LLC increased its stake in Johnson & Johnson by 26.9% during the third quarter. Warren Street Wealth Advisors LLC now owns 1,833 shares of the company’s stock worth $285,000 after acquiring an additional 388 shares during the last quarter. Blue Fin Capital Inc. increased its stake in Johnson & Johnson by 0.6% during the third quarter. Blue Fin Capital Inc. now owns 20,686 shares of the company’s stock worth $3,222,000 after acquiring an additional 132 shares during the last quarter. WestEnd Advisors LLC increased its stake in Johnson & Johnson by 2.3% during the third quarter. WestEnd Advisors LLC now owns 214,315 shares of the company’s stock worth $33,380,000 after acquiring an additional 4,895 shares during the last quarter. Finally, Financial & Tax Architects LLC increased its stake in Johnson & Johnson by 6.6% during the third quarter. Financial & Tax Architects LLC now owns 33,956 shares of the company’s stock worth $5,289,000 after acquiring an additional 2,110 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on JNJ shares. Morgan Stanley reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Bank of America dropped their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, April 15th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Stock Down 0.8 %

Shares of NYSE JNJ opened at $149.92 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.91 and a current ratio of 1.17. The firm has a market capitalization of $361.27 billion, a price-to-earnings ratio of 9.35, a PEG ratio of 2.49 and a beta of 0.55. The stock has a 50 day moving average price of $154.44 and a 200 day moving average price of $155.08. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.68 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.31%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 29.68%.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.